Effect of Dexmedetomidine on the Prevention of Delirium

The Effect of Intranasal Dexmedetomidine on the Prevention of Delirium in Elderly Patients Admitted to the Intensive Care Unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160307026950N77

Enrollment

100

Registered

2026-01-28

Start date

2026-01-21

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Delirium

Interventions

Intervention 1: Intervention group: Administration of a single intranasal dose of dexmedetomidine, 1 microgram per kilogram of body weight, diluted to a final volume of 1 milliliter, and administered

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients admitted to the intensive care unit American Society of Anesthesiologists (ASA) status between 1 and 2 Patient age above 65 years Absence of delirium upon admission according to the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) Written informed consent from the patient to participate in the study

Exclusion criteria

Exclusion criteria: Active psychiatric illness ( such as schizophrenia, severe depression) or use of strong psychotropic medications prior to admission Predicted ICU stay of less than 48 hours History of allergy or contraindication to anesthetics and sedative medications

Design outcomes

Primary

Measure	Time frame
Delirium occurrence based on the Confusion Assessment Method for the Intensive Unit Care. Timepoint: 24 and 48 hours after the intervention. Method of measurement: Confusion Assessment Method for the Intensive Unit Care.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Nazemroaya

Esfahan University of Medical Sciences

behzad_nazem@med.mui.ac.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026